SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

nenocorilant

CORT·CORCEPT THERAPEUTICS INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1b/2
Time to market
If Phase 1b/2 data are positive (expected end of 2027), a Phase 2 or pivotal trial would follow, putting potential approval several years away, likely 2029 or later.
Why 3/10
No hard binary catalyst (PDUFA or pivotal readout) is scheduled for nenocorilant in the next ~12 months. Corcept expects Phase 1b dose-finding results from the SYNERGY trial by the end of 2027. The drug is an early-stage (Phase 1b/2) asset at a commercial-stage company with multiple approved products and a major PDUFA for relacorilant on December 17, 2026, which will dominate the stock's near-term moves.
Actionable Insight NEUTRAL

The next catalyst for nenocorilant is Phase 1b dose-finding data from the SYNERGY trial, which Corcept expects by the end of 2027. The stock's near-term binary is the relacorilant PDUFA on December 17, 2026, which will dominate investor attention. Nenocorilant is too early-stage to move the stock independently in the near term.

Price Chart

Loading chart...

Executive Summary

Nenocorilant (also known as CORT125236, formerly ORIC-101) is an oral, selective glucocorticoid receptor (GR) antagonist being developed by Corcept Therapeutics (NASDAQ: CORT) for oncology. It is currently in a Phase 1b/2 SYNERGY trial (NCT07276373) combining nenocorilant with Bristol Myers Squibb's nivolumab (Opdivo) in patients with advanced solid tumors. The Phase 1b dose-finding portion is still enrolling, and Corcept expects results by the end of 2027. The drug's predecessor (ORIC-101) showed acceptable safety but limited efficacy in a prior Phase 1b prostate cancer trial. Nenocorilant is an early-stage pipeline asset at a profitable commercial-stage company whose near-term stock value is dominated by the December 17, 2026 PDUFA for relacorilant in Cushing's syndrome.

How It Works

Nenocorilant is a pill that blocks the glucocorticoid receptor (GR), a protein that cortisol and similar hormones activate. In many cancers, GR signaling helps tumors resist chemotherapy and immunotherapy. By blocking GR, nenocorilant aims to make cancer cells more sensitive to treatment. It is being tested in combination with the immunotherapy drug nivolumab (Opdivo) in patients with advanced solid tumors.

Trial Status

The SYNERGY trial (NCT07276373) is a Phase 1b/2 open-label study evaluating nenocorilant plus nivolumab in advanced solid malignancies. The Phase 1b dose-finding portion is actively recruiting (estimated 30 patients). A trial-in-progress poster was presented at ASCO 2026. Corcept expects Phase 1b results by the end of 2027.

The Two-Sided Case

▲ Bull Case4
Nenocorilant targets a novel mechanism (glucocorticoid receptor antagonism) to overcome resistance to checkpoint inhibitors, potentially addressing a large unmet need in patients who do not respond to PD-1/L1 therapies.
Corcept is a profitable, commercial-stage company with $544.6M in cash and investments (June 2026), providing ample funding to advance the SYNERGY trial without dilution risk.
The SYNERGY trial uses nivolumab (Opdivo, BMS), a well-established immunotherapy, reducing combination risk versus an unproven partner drug.
Corcept's expertise in selective GR modulation (validated by approved Korlym and Lifyorli) gives it a strong scientific foundation for developing GR antagonists in oncology.
▼ Bear Case4
Prior Phase 1b data for ORIC-101 (same molecule) in metastatic prostate cancer showed acceptable tolerability but no clinical benefit when combined with enzalutamide, raising questions about GR antagonism as a cancer strategy.
The SYNERGY trial is still recruiting with only 30 planned patients in Phase 1b; early-stage oncology trials have a high failure rate.
Nenocorilant is a tiny part of Corcept's pipeline; the company's value is driven by approved products Korlym and Lifyorli and the upcoming relacorilant PDUFA, not this early-stage asset.
Multiple insiders sold shares in October-November 2026 at prices above $80, though these were 10b5-1 plan trades.

Upcoming Catalysts

  • Phase 1b dose-finding data from SYNERGY trial expected by end of 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report

Sources · 12

Hover a chip for the title
1 adisinsight.springer.com2 ascopubs.org3 corcept.com4 corcept.com5 clinicaltrials.gov6 marketbeat.com7 tradingkey.com8 advfn.com9 pmc.ncbi.nlm.nih.gov10 ir.corcept.com11 ir.corcept.com12 stockinvest.us